Adicet Bio, Inc. (ACET)
US — Healthcare Sector
Automate Your Wheel Strategy on ACET
With Tiblio's Option Bot, you can configure your own wheel strategy including ACET - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ACET
- Rev/Share 0.0
- Book/Share 1.7727
- PB 0.4337
- Debt/Equity 0.1006
- CurrentRatio 9.3368
- ROIC -0.7025
- MktCap 63587140.0
- FreeCF/Share -1.0684
- PFCF -0.6535
- PE -0.5968
- Debt/Assets 0.0849
- DivYield 0
- ROE -0.5905
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | ACET | Guggenheim | -- | Buy | -- | $7 | Sept. 30, 2024 |
| Downgrade | ACET | H.C. Wainwright | Buy | Neutral | -- | -- | Sept. 11, 2024 |
News
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know
ACET
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Adicet Bio (ACET) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
About Adicet Bio, Inc. (ACET)
- IPO Date 2018-01-26
- Website https://www.adicetbio.com
- Industry Biotechnology
- CEO Mr. Chen Schor BA, CPA, M.B.A.
- Employees 152
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.